Eton Pharmaceuticals, Inc. (ETON)
62.94
-1.49
(-2.31%)
USD |
NASDAQ |
Aug 25, 16:00
63.98
+1.04
(+1.65%)
After-Hours: 19:59
Eton Pharmaceuticals Enterprise Value : 1.825B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 1.825B |
| August 21, 2026 | 1.798B |
| August 20, 2026 | 1.697B |
| August 19, 2026 | 1.742B |
| August 18, 2026 | 1.797B |
| August 17, 2026 | 1.749B |
| August 14, 2026 | 1.668B |
| August 13, 2026 | 1.157B |
| August 12, 2026 | 1.179B |
| August 11, 2026 | 1.192B |
| August 10, 2026 | 1.238B |
| August 07, 2026 | 1.264B |
| August 06, 2026 | 1.309B |
| August 05, 2026 | 1.303B |
| August 04, 2026 | 1.299B |
| August 03, 2026 | 1.279B |
| July 31, 2026 | 1.316B |
| July 30, 2026 | 1.389B |
| July 29, 2026 | 1.364B |
| July 28, 2026 | 1.322B |
| July 27, 2026 | 1.199B |
| July 24, 2026 | 1.207B |
| July 23, 2026 | 1.251B |
| July 22, 2026 | 1.235B |
| July 21, 2026 | 1.225B |
| Date | Value |
|---|---|
| July 20, 2026 | 1.164B |
| July 17, 2026 | 1.200B |
| July 16, 2026 | 1.054B |
| July 15, 2026 | 1.092B |
| July 14, 2026 | 1.064B |
| July 13, 2026 | 1.059B |
| July 10, 2026 | 1.038B |
| July 09, 2026 | 1.058B |
| July 08, 2026 | 1.026B |
| July 07, 2026 | 1.070B |
| July 06, 2026 | 1.078B |
| July 02, 2026 | 1.063B |
| July 01, 2026 | 1.039B |
| June 30, 2026 | 1.026B |
| June 29, 2026 | 1.017B |
| June 26, 2026 | 988.35M |
| June 25, 2026 | 964.27M |
| June 24, 2026 | 941.29M |
| June 23, 2026 | 927.88M |
| June 22, 2026 | 906.81M |
| June 18, 2026 | 900.25M |
| June 17, 2026 | 907.91M |
| June 16, 2026 | 896.69M |
| June 15, 2026 | 891.22M |
| June 12, 2026 | 875.90M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Nektar Therapeutics | 1.967B |
| Pfizer Inc. | 211.20B |
| Elite Pharmaceuticals, Inc. | 278.03M |
| Daré Bioscience, Inc. | 6.305M |
| Liquidia Corp. | 6.160B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 11.58M |
| Revenue (Quarterly) | 37.59M |
| Total Expenses (Quarterly) | 26.01M |
| EPS Diluted (Quarterly) | 0.3531 |
| Gross Profit Margin (Quarterly) | 67.61% |
| Profit Margin (Quarterly) | 30.80% |
| Earnings Yield | 0.60% |
| Operating Earnings Yield | 0.86% |
| Normalized Earnings Yield | 0.6090 |